Aclaris Therapeutics (ACRS) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Aclaris Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 1 sold $1.4M of ACRS stock on the open market.
Get emailed when insiders cluster-buy stocks like ACRS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ACRS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $1.4M | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Aclaris Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 1 insider reported sales totaling $1.4M. 0 of 1 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ACRS earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 6, 2026 | +11.8% | None | -7.1%S&P +0.5% | +4.4% |
| May 7, 2026 | +14.6% | Sold $1.4M | +3.1%S&P +0.5% | -11.6% |
| Feb 26, 2026 | -9.3% | None | -13.3%S&P -1.0% | +22.6% |
| Nov 6, 2025 | -5.0% | None | +2.7%S&P -1.0% | +25.9% |
| Aug 7, 2025 | -4.3% | None | +5.2%S&P +0.7% | +28.8% |
| May 8, 2025 | +13.6% | None | +0.8%S&P +0.6% | +21.4% |
| Feb 27, 2025 | -4.5% | None | -5.2%S&P -0.1% | -20.1% |
| Nov 6, 2024 | +83.5% | None | +10.4%S&P +3.3% | +60.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Apr 27SEC | Braden Michael Leonard10% Owner | Sell | 300,00013,950,000 held (−2%) | $4.53 | $1.4M | -15.5% | — |
Insiders at Aclaris Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Braden Michael Leonard10% Owner | — | $1.4M | Apr 27, 2026 | — |
ACRS stock: common questions
Are Aclaris Therapeutics, Inc. insiders buying ACRS stock?
In the past 12 months, 0 insiders reported open-market purchases of ACRS worth $0.
Are Aclaris Therapeutics, Inc. insiders selling ACRS stock?
1 insiders reported sales worth $1.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ACRS's 52-week range?
Over the past year ACRS has traded between $1.81 and $6.54. It last closed at $3.83 on Oct 9, 2026.